Next Article in Journal
State-of-the-Art Review on Immersive Virtual Reality Interventions for Colonoscopy-Induced Anxiety and Pain
Previous Article in Journal
Does Additional Dietary Supplementation Improve Physiotherapeutic Treatment Outcome in Tendinopathy? A Systematic Review and Meta-Analysis
Previous Article in Special Issue
Relation of Baseline Neutrophil Gelatinase-Associated Lipocalin (NGAL) Levels and Contrast-Induced Nephropathy following Percutaneous Coronary Intervention among Chronic Kidney Disease Patients
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Kim et al. Diagnostic Value of Multiple Serum Biomarkers for Vancomycin-Induced Kidney Injury. J. Clin. Med. 2021, 10, 5005

1
Samsung Medical Center, Department of Laboratory Medicine and Genetics, School of Medicine, Sungkyunkwan University, Seoul 06351, Korea
2
Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul 06351, Korea
3
Samsung Medical Center, Department of Clinical Pharmacology & Therapeutics, School of Medicine, Sungkyunkwan University, Seoul 06351, Korea
4
Department of Health Science and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul 06351, Korea
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
J. Clin. Med. 2022, 11(6), 1667; https://doi.org/10.3390/jcm11061667
Submission received: 7 December 2021 / Accepted: 11 March 2022 / Published: 17 March 2022
Error in Table
In the original publication [1], there was a mistake in “Table 2. Serum biomarker concentrations in the (A) screening test by Luminex assay (n = 55) and the (B) validation test by ELISA (n = 72).” as published. ** Table 2(B) was identical to Table 2(A)**. The corrected “Table 2. Serum biomarker concentrations in the (A) screening test by Luminex assay (n = 55) and the (B) validation test by ELISA (n = 72).” appears below.
Text Correction
There was an error in the original publication. **A word needs to be replaced in the sentence**.
A correction has been made to **3. Discussion**, **Paragraph 8**:
**There are some limitations that must be noted. First, owing to the retrospective nature of our study, the study evaluated the diagnostic value of the biomarkers rather than their predictive value for VIKI. Secondly, this study identified candidate serum biomarkers that have potential for the diagnosis of VIKI, but the current design could not show their specificity for VIKI. Indeed, we are conducting an additional experiment with a control group consisting of patients with AKI induced by causes other than vancomycin to identify the specificity of the biomarkers for VIKI. Lastly, this research was a single-center study with a limited number of subjects with heterogeneous baseline conditions, preventing our results from being free of bias. Large-scale, multi-center studies would be required to establish the credibility of our findings.**
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Kim, S.-M.; Lee, H.-S.; Kim, M.-J.; Park, H.-D.; Lee, S.-Y. Diagnostic Value of Multiple Serum Biomarkers for Vancomycin-Induced Kidney Injury. J. Clin. Med. 2021, 10, 5005. [Google Scholar] [CrossRef] [PubMed]
Table 2. Serum biomarker concentrations in the (A) screening test by Luminex assay (n = 55) and the (B) validation test by ELISA (n = 72).
Table 2. Serum biomarker concentrations in the (A) screening test by Luminex assay (n = 55) and the (B) validation test by ELISA (n = 72).
(A)
VIKI
(n = 20)
ControlVIKI vs. ControlVIKI vs. Non-VIKI vs. HCPost Hoc Comparison
Non-VIKI
(n = 15)
HC
(n = 20)
VIKI vs. HCVIKI vs. Non-VIKINon-VIKI vs. HC
IL-18 (pg/mL)849 (468–1352)455 (347–766)229 (190–303)<0.001<0.001<0.0010.021<0.001
TNF-R1 (pg/mL)6797 (4085–11,770)3735 (2411–4920)1017 (918–1120)<0.001<0.001<0.0010.001<0.001
CXCL10 (pg/mL)563.3 (189.0–1161.3)199.8 (139.6–305.7)77.9 (61.7–89.3)<0.001<0.001<0.0010.031<0.001
Osteopontin (ng/mL)193.1 (103.2–334.0)73.8 (42.5–109.7)17.8 (16.1–28.1)<0.001<0.001<0.001<0.001<0.001
TFF3 (ng/mL)8.5 (4.8–14.9)2.9 (1.7–4.7)1.9 (1.6–2.2)<0.001<0.001<0.001<0.0010.023
Clusterin (μg/mL)0.20 (0.15–0.24)0.19 (0.15–0.22)0.23 (0.20–0.24)0.4890.073
Cystatin C (mg/L)2.7 (2.2–3.2)1.2 (1.0–1.6)1.2 (1.1–1.3)<0.001<0.001<0.001<0.0010.994
RBP4 (μg/mL)30.4 (23.4–41.4)19.5 (13.2–36.2)62.3 (51.5–82.7)0.057<0.001<0.0010.089<0.001
NGAL (ng/mL)130.4 (101.1–155.1)70.5 (49.0–116.8)55.4 (37.0–60.3)<0.001<0.001<0.0010.0060.105
(B)
VIKI
(n = 28)
ControlVIKI vs. ControlVIKI vs. Non-VIKI vs. HCPost Hoc Comparison
Non-VIKI
(n = 21)
HC
(n = 23)
VIKI vs. HCVIKI vs. Non-VIKINon-VIKI vs. HC
IL-18 (pg/mL)461 (363–798)266 (161–442)122 (95–164)<0.001<0.001<0.0010.017<0.001
TNF-R1 (pg/mL)7915 (4655–12,871)2845 (1820–4444)1149 (975–1336)<0.001<0.001<0.0010.0020.005
CXCL10 (pg/mL)509.2 (184.2–748.8)221.2 (135.4–317.5)96.0 (66.4–125.4)<0.001<0.001<0.0010.034<0.001
Osteopontin (ng/mL)9.5 (5.3–14.6)3.5 (2.3–7.2)1.0 (0.8–1.2)<0.001<0.001<0.001<0.001<0.001
TFF3 (ng/mL)27.5 (16.8–39.0)8.4 (6.07–12.4)6.5 (5.7–8.9)<0.001<0.001<0.001<0.0010.394
Cystatin C (mg/L)2.3 (1.6–2.8)0.8 (0.7–1.0)0.7 (0.6–0.9)<0.001<0.001<0.001<0.0010.071
NGAL (ng/mL)157.5 (97.3–362.1)96.9 (53.3–141.7)38.8 (28.1–48.9)<0.001<0.001<0.0010.011<0.001
Note: p-value < 0.05 was considered statistically significant. Significant values are indicated in bold. Abbreviations: VIKI, vancomycin-induced kidney injury; HC, healthy control; IL-18, interleukin-18; TNF-R1, tumor necrosis factor receptor 1; CXCL10, C-X-C motif chemokine ligand 10; TFF3, trefoil factor-3; RBP4, retinol binding protein 4; and NGAL, neutrophil gelatinase-associated lipocalin.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Kim, S.-M.; Lee, H.-S.; Kim, M.-J.; Park, H.-D.; Lee, S.-Y. Correction: Kim et al. Diagnostic Value of Multiple Serum Biomarkers for Vancomycin-Induced Kidney Injury. J. Clin. Med. 2021, 10, 5005. J. Clin. Med. 2022, 11, 1667. https://doi.org/10.3390/jcm11061667

AMA Style

Kim S-M, Lee H-S, Kim M-J, Park H-D, Lee S-Y. Correction: Kim et al. Diagnostic Value of Multiple Serum Biomarkers for Vancomycin-Induced Kidney Injury. J. Clin. Med. 2021, 10, 5005. Journal of Clinical Medicine. 2022; 11(6):1667. https://doi.org/10.3390/jcm11061667

Chicago/Turabian Style

Kim, Sang-Mi, Hyun-Seung Lee, Min-Ji Kim, Hyung-Doo Park, and Soo-Youn Lee. 2022. "Correction: Kim et al. Diagnostic Value of Multiple Serum Biomarkers for Vancomycin-Induced Kidney Injury. J. Clin. Med. 2021, 10, 5005" Journal of Clinical Medicine 11, no. 6: 1667. https://doi.org/10.3390/jcm11061667

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop